“Increased Use of NHP Models”
The increasing use of non-human primates (NHPs) as preclinical models reflects their genetic and physiological similarity to humans, making them particularly suited for studying complex diseases such as cancer, genetic disorders, and neurological conditions. NHPs provide critical insights into disease mechanisms and therapeutic responses, supporting the development of advanced treatments like viral vector-based gene therapies. Their role is further emphasized by regulatory requirements for safety and efficacy data from NHP studies to advance treatments to clinical trials. This trend underscores a growing focus on leveraging NHPs for more accurate and comprehensive evaluations in preclinical research.
Frequently Asked Questions
The market is segmented based on Global Viral Vectors-Based Gene Therapy for Non-Human Primates Market Segmentation, By Type of Viral Vectors (Adenoviral Vectors, Adeno-Associated Viral (AAV) Vectors, Lentiviral Vectors, Retroviral Vectors, Others), Delivery Method (In Vivo Gene Therapy, Ex Vivo Gene Therapy), Source (Recombinant Viral Vectors, Native Viral Vectors), Application (Oncology, Neurological Disorders, Genetic Disorders, Cardiovascular Diseases, Infectious Diseases, Others), End User (Pharmaceutical Companies, Biotechnology Companies, Research Institutions, Contract Research Organizations (CROs) – Industry Trends and Forecast to 2032
.
The Global Viral Vectors Based Gene Therapy For Non Human Primates Market size was valued at USD 1.26 USD Billion in 2024.
The Global Viral Vectors Based Gene Therapy For Non Human Primates Market is projected to grow at a CAGR of 15.4% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, Rest of South America.
